Catalent launches direct-to-patient clinical supply services
Multiple options provide increased flexibility for sponsors.
Catalent has launched FlexDirect, a new direct-to-patient service for clinical trials. The FlexDirect service provides sponsors with the choice of site-to-patient distribution, or Catalent’s new pharmacy-to-patient service, both of which can be combined with standard distribution of clinical supplies to offer a customized hybrid approach as needed.
Catalent’s pharmacy service is located within the same facility as standard distribution, enabling clinical supplies distributed to both clinical sites and directly to patients to originate from a single location, eliminating the need to maintain separate inventories.
The FlexDirect service offers benefits to both sponsors and patients undertaking clinical trials. For sponsors, direct-to-patient distribution of clinical supplies (patient kits) supports improved recruitment and retention of patients by delivering treatments directly to their homes, removing barriers such as transportation challenges and addressing the constraints of underlying health conditions that may hinder patients’ visits to clinical sites.
The service also makes trials more patient-centric by improving convenience, supporting busy lifestyles and reducing the number of clinical visits that are necessary. Site-to-patient services are available in the US and Europe. Pharmacy-to-patient services are accessible in the US via Catalent’s on-site pharmacy at its Philadelphia location, offering sponsors a streamlined and compliant solution that eliminates the need for clinical sites to physically receive, store and dispense patient kits.
“The nature of clinical trials has evolved, but the needs for a trial to maintain patient engagement and ensure dosing regimens are adhered to remain paramount, and direct-to-patient supply reduces the burden of patients to visit clinical sites and maintain participation,” explained Kristen DeVito, Global Director Clinical Supply Services. “FlexDirect increases the options available to study sponsors and offers increased flexibility in distribution, reducing the strain on clinical sites by offering a pharmacy-based service and promoting patient retention.”
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance